The Ensign Group, Inc.
ENSG
$176.32
-0.15%
The Ensign Group, Inc. operates a decentralized network of post-acute healthcare providers across the United States, delivering skilled nursing, rehabilitation therapy, assisted living, home health and hospice, mobile ancillary, and urgent care services through locally managed subsidiaries, with Medicare and Medicaid programs supplying the majority of revenue. The company is best understood as a serial acquirer and operator of turnaround skilled nursing facilities, structured around two segments — Skilled Services (roughly $1.42B of the most recent quarterly revenue) and Standard Bearer, its captive-REIT property arm that owns facilities and leases them back to operating affiliates. The current investor narrative centers on the durability of Ensign's acquisition-driven growth engine and margin improvement, reinforced by a raised guidance headline in late August 2026 and a strong Q3 print (revenue +14.5% YoY) that has kept sell-side sentiment constructive. Debate now hinges on whether the company can sustain double-digit top-line growth and operating leverage as it digests a heavy acquisition cadence, and whether the premium multiple embedded in the shares is warranted given a modest trailing earnings base and thin net margins.…
ENSG
The Ensign Group, Inc.
$176.32
Related headlines
Investment Opinion: Should I buy ENSG Today?
Rating: Buy (accumulate on weakness), with the caveat that the stock is at the top of its range and offers no valuation cushion. The core thesis is that Ensign's decentralized acquisition-and-turnaround engine is still compounding — Q3 2026 revenue of $1.484B grew 14.47% YoY and marked the fourth consecutive quarterly record — while operating leverage is genuinely materializing (gross margin 16.40% → 16.65% → 16.86% across Q1–Q3, operating margin 8.50% → 9.30% in Q3). The analyst consensus leans constructive (3 Buy/Outperform — RBC, UBS, Oppenheimer — versus 1 Hold from Truist), and the $9.57 consensus EPS against the $188.41 price implies roughly 19.7x forward earnings versus a 29.0x trailing PE, meaning the premium is being paid with expected earnings growth rather than requiring further multiple expansion.
Supporting evidence is broad: revenue growth of 14.47% YoY is far above low-single-digit skilled nursing sector norms; net income rose from $99.7M in Q2 to $104.3M in Q3 on a 7.03% net margin; TTM free cash flow of $509.9M on a ~$9.98B market cap is a ~5.1% FCF yield; ROE of 15.41% is solid for a capital-intensive operator; and interest expense of just $2.3M against $140.2M pre-tax income means the 1.86x debt-to-equity is comfortably serviced. Momentum confirms the fundamental story — +7.14% over the past month versus -2.26% for SPY, a +9.40pp relative strength spread, with the stock at $188.41 pressing above its November 4 high of $188.31.
The risks that could invalidate this thesis are (1) margin stall — if Q4 gross margin slips back toward the 16.4% Q1 level as acquired facilities are digested, the operating-leverage narrative breaks; (2) reimbursement and wage pressure — with Medicare/Medicaid supplying the majority of revenue and only a 7.03% net margin, a rate adjustment or labor inflation spike hits earnings disproportionately; and (3) valuation compression — at 24.0x EV/EBITDA, 1.97x PS, and 4.47x book, ENSG trades at a clear premium to peers at mid-to-high single-digit EV/EBITDA, and its 29.0x trailing PE sits near the top of its 20–30x historical band. This Buy would downgrade to Hold if gross margin falls below 16.4% or the forward EPS estimate drifts toward the $8.71 low, and to Sell on a decisive break below the $169–$172 support shelf. Verdict: fairly valued to modestly full — not cheap, but the growth and margin trajectory justify the premium as long as execution holds.
Sign up to view all
ENSG 12-Month Price Forecast
The forward setup is constructive: Ensign is compounding revenue at 14.47% while demonstrating real operating leverage, and the ~19.7x forward multiple means the premium is being earned by expected earnings growth rather than demanding further multiple expansion. Analyst sentiment is supportive but thin — 3 Buy/Outperform versus 1 Hold across only 4 analysts, with an 18% EPS dispersion ($8.71–$10.27) that signals real uncertainty around acquisition timing and margin realization. The main constraint is price: at 24.0x EV/EBITDA and 1.97x PS, the stock sits near the top of its 20–30x historical PE band and at 100% of its 180-day range, leaving little cushion for an execution miss. I would upgrade to high confidence on a decisive breakout above $190 accompanied by Q4 gross margin above 16.9%, and downgrade to neutral if gross margin slips below 16.4% or the stock breaks below the $169–$172 support shelf.
Wall Street consensus
Coverage is thin but constructive: only 4 analysts cover Ensign, with a distribution that skews bullish — RBC Capital (Outperform), UBS (Buy), and Oppenheimer (Outperform) versus Truist Securities (Hold), implying roughly 3 Buys and 1 Hold, or a consensus leaning toward Buy/Outperform. The consensus EPS estimate is $9.57 (range $8.71–$10.27) on average revenue of $7.24B (range $7.09B–$7.34B), which against the current $188.41 price implies a forward earnings multiple of roughly 19.7x — notably below the 29.0x trailing PE, consistent with expected earnings growth. No explicit price targets were provided in the dataset, so implied upside to a consensus target cannot be calculated; the signal from estimates alone is modestly positive.
The target range is wide on earnings (a $1.56 spread between the $8.71 low and $10.27 high, or ~18% around the mean), signaling meaningful uncertainty about acquisition timing and margin realization. The high end ($10.27 EPS, $7.34B revenue) assumes continued accretive deal flow, occupancy gains, and operating leverage; the low end ($8.71 EPS, $7.09B revenue) prices in slower integration, reimbursement pressure, or wage inflation. Institutional ratings have been stable rather than directional — RBC, UBS, and Oppenheimer have reiterated Outperform/Buy through late 2026 while Truist has held at Hold since mid-2025 — suggesting conviction is intact but not broadening. With only 4 analysts, price discovery is less efficient than for large-cap peers, which can amplify volatility around earnings and guidance updates.
Bulls vs Bears: ENSG Investment Factors
The bull case currently has the stronger evidence: 14.47% revenue growth, three consecutive quarters of margin expansion, a ~19.7x forward multiple against 29.0x trailing, and +9.40pp relative strength versus the S&P over the past month all point to a fundamentals-driven re-rating. The bear case rests less on deteriorating data than on price: 24.0x EV/EBITDA and 1.97x PS are premium multiples for a 7% net-margin skilled nursing operator, and the -31.83% drawdown shows how violently the stock can reprice when execution slips. The single most important tension is whether operating leverage can keep expanding margins as Ensign digests a heavy acquisition cadence — if gross margin holds above 16.8% and the roll-up stays accretive, the premium is earned; if integration slows or reimbursement tightens, the multiple has room to compress toward its 20–30x historical band's lower end. With only 4 analysts and an 18% EPS dispersion, conviction should be sized accordingly.
Bullish
- Double-digit revenue growth accelerating: Q3 2026 revenue of $1.484B grew 14.47% YoY from $1.296B, and each of the last four quarters has set a new high ($1.361B → $1.389B → $1.440B → $1.484B). This cadence is consistent with the ~$7.24B forward consensus and shows the acquisition-and-turnaround engine is compounding rather than stalling.
- Operating leverage is real and sequential: Gross margin rose from 16.40% in Q1 to 16.65% in Q2 to 16.86% in Q3, while operating margin expanded from 8.50% in Q2 to 9.30% in Q3 and net income climbed from $99.7M to $104.3M. Margin expansion on a rising revenue base is the clearest evidence that acquired facilities are being turned around and cost discipline is holding.
- Forward multiple well below trailing: At $188.41, the stock trades at 29.0x trailing PE but only ~19.7x the $9.57 consensus EPS, implying roughly 47% earnings growth is already expected. That gap means the premium multiple is being paid with future earnings rather than requiring further multiple expansion.
- Strong relative strength and breakout: ENSG is up 7.14% over the past month against a -2.26% SPY move, a +9.40pp relative strength spread, and sits at $188.41 — effectively 100% of its 180-day range and just above the November 4 high of $188.31. Momentum leadership of this magnitude alongside raised guidance suggests a fundamentals-driven re-rating, not a bounce.
Bearish
- Premium valuation versus sector peers: ENSG trades at 1.97x PS, 4.47x book, and 24.0x EV/EBITDA — multiples that are rich for a skilled nursing operator where peers typically sit at mid-to-high single-digit EV/EBITDA. The premium leaves little cushion: any deceleration in the roll-up or reimbursement pressure would compress the multiple sharply.
- Thin margins with structural reimbursement risk: Net margin is only 7.03% and gross margin 16.86%, both structurally thin because Medicare and Medicaid supply the majority of revenue. A single reimbursement rate adjustment or wage inflation spike can erase a large share of the $104.3M quarterly net income given how little buffer exists.
- Growth is acquisition-dependent and levered: Q3 alone consumed $164.0M of cash for acquisitions against $240.2M of operating cash flow, and debt-to-equity stands at 1.86x. The roll-up can only continue at this pace while debt capacity and FCF conversion hold, making the growth rate partly a financing decision rather than a purely organic outcome.
- Severe drawdown history despite healthcare label: The stock suffered a -31.83% max drawdown within the observed period, falling from prior peaks to the June 11 low of $147.13. That volatility profile contradicts the defensive reputation of healthcare and means a 30%+ peak-to-trough swing is a realistic risk even in an intact uptrend.
ENSG Technical Analysis
Ensign is in a sustained, if choppy, uptrend: the stock is up 6.27% over the trailing year and 8.33% year-to-date, and at $188.41 it sits at the very top of its 180-day trading band, which ran from a low of $147.13 (June 11) to the current level — effectively 100% of the observed 52-week range. That positioning signals momentum leadership rather than a value entry point, and it comes after a sharp mid-year drawdown of -31.83% from the prior peak, meaning the current advance is a full recovery and breakout rather than a fresh trend. The stock is now pressing into blue-sky territory above the prior $188.31 high set on November 4, a level that must hold to validate the breakout.
Short-term momentum is clearly accelerating and diverging positively from the longer-term trend: the stock is up 7.14% over the past month versus a 3.72% three-month gain and 6.04% over six months, meaning the bulk of recent performance has been concentrated in the last four weeks. Critically, this is happening against a weak tape — the S&P 500 (SPY) fell 2.26% over the same month, giving Ensign a relative strength of +9.40 percentage points, and it also outperformed over three months (+6.55pp) and six months (+3.91pp). The one-year relative strength remains negative at -6.00pp, confirming that the stock spent much of the past year lagging the market before this recent burst; the divergence suggests a genuine re-rating on improved fundamentals (raised guidance, strong Q3) rather than a mean-reversion bounce, though the sharpness of the move raises near-term overextension risk.
Key technical levels are well defined: support sits at the June low of $147.13, with a secondary shelf around $169–$172 where the stock consolidated through September and October, while resistance is the current all-time-high zone near $188.41, just above the November 4 peak of $188.31. A decisive breakout above $188–$190 on volume would confirm the uptrend and likely invite momentum buyers, whereas a failure and breakdown below $172 would flag a false breakout and re-open the $147 area. Volatility is meaningful — the -31.83% max drawdown within the period underscores that this is not a low-beta defensive name despite its healthcare classification — so position sizing should account for the potential for 30%+ peak-to-trough swings even within an intact uptrend.
Beta
—
—
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-1.7%
Cumulative gain past year
| Period | ENSG Return | S&P 500 |
|---|---|---|
| 1m | +1.7% | -9.7% |
| 3m | -1.8% | -9.9% |
| 6m | +2.5% | -7.5% |
| 1y | -1.7% | +4.7% |
| ytd | +1.4% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ENSG Fundamental Analysis
Revenue is growing at a healthy and stable clip: Q3 2026 revenue reached $1.484B, up 14.47% year-over-year from $1.296B in Q3 2025, and the sequential cadence has been consistent — $1.389B in Q1, $1.440B in Q2, and $1.484B in Q3, each quarter setting a new high. The Skilled Services segment dominates at $1.422B of segment revenue versus just $47.7M from Standard Bearer, so the operating business is the growth engine while the captive REIT is a supporting, capital-recycling structure. The trajectory implies roughly $5.9–6.0B in annualized revenue and is consistent with the analyst consensus of ~$7.24B for the forward year, suggesting the acquisition pipeline and same-store occupancy gains remain the primary drivers of the investment case.
Profitability is solid and improving: Q3 net income was $104.3M (net margin 7.03%) on gross profit of $250.2M, a 16.86% gross margin, with operating income of $138.0M (9.30% operating margin) and EBITDA of $175.1M (11.80% EBITDA margin). The margin trend is clearly upward — gross margin rose from 16.40% in Q1 to 16.65% in Q2 to 16.86% in Q3, and operating margin expanded from 8.99% to 8.50% to 9.30% over the same span, while net income climbed from $99.7M to $99.7M to $104.3M. For a skilled nursing operator, these are respectable but structurally thin margins (typical of the industry given Medicare/Medicaid reimbursement pressure), and the sequential expansion points to operating leverage from acquisitions and cost discipline rather than one-off items.
Balance sheet and cash generation are adequate but levered: debt-to-equity stands at 1.86x, the current ratio is 1.42x, and TTM free cash flow is $509.9M against a $9.98B market cap, implying an FCF yield of roughly 5.1%. ROE is 15.41%, a solid return for a capital-intensive operator, and quarterly operating cash flow of $240.2M comfortably funded $47.6M of capex and $164.0M of acquisitions in Q3, leaving $337.6M of cash. The leverage is elevated for the sector, but interest coverage is very strong (interest expense of just $2.3M against $140.2M pre-tax income), so the debt is manageable; the key risk is that growth is partly acquisition-funded, meaning FCF conversion and debt capacity will determine how long the roll-up can continue at this pace.
Quarterly Revenue
$1.5B
2026-09
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
16.9%
Latest Quarter
Free Cash Flow
$509910000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ENSG Overvalued?
Because Ensign is profitable (Q3 net income of $104.3M, positive TTM earnings), the PE ratio is the appropriate primary metric. The trailing PE is 29.0x, while the forward PE is 2.06x — a gap that is almost certainly a data artifact (the forward figure appears to be mislabeled or reflects a PEG-style input rather than a true forward multiple), so the more reliable read is the trailing 29.0x PE against a PEG of 2.06x and a price-to-sales of 1.97x. On a normalized basis, a ~29x trailing multiple for a 14%+ grower with 7% net margins implies the market is pricing in continued double-digit growth and margin expansion.
Relative to the broader healthcare facilities sector, Ensign screens at a premium on most measures: its 1.97x PS ratio, 4.47x price-to-book, and 24.0x EV/EBITDA are rich for a skilled nursing operator, where peers typically trade at mid-to-high single-digit EV/EBITDA multiples. The premium is defensible given Ensign's superior growth (14.5% revenue growth vs. low-single-digit sector norms), 15.4% ROE, and its proven acquisition-and-turnaround model, but it leaves little room for execution error — any slowdown in the roll-up or reimbursement pressure would compress the multiple sharply.
Historically, Ensign's own PE has ranged widely: it was 23.9x at Q3 2026, 29.1x in Q1 2026, 26.2x at year-end 2025, and as high as 71.9x in Q4 2023 (a depressed-earnings quarter), with a more typical band of 20–30x over the past several years. At 29.0x trailing, the stock is near the upper end of its normal band, while its PS of 1.97x is actually below the 6–8x levels seen through 2024–2025 (reflecting the much larger revenue base). The read-through is that the market is pricing in optimistic but not extreme expectations — the valuation is full, and further upside likely requires continued earnings beats rather than multiple expansion.
PE
29.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 17x~30x
vs. Industry Avg
18.9x
Industry PE ~18.9x*
EV/EBITDA
24.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the acquisition-funded growth model and thin margins. Debt-to-equity of 1.86x is elevated for the sector, and Q3 required $164.0M of acquisition outlays against $240.2M of operating cash flow, so the roll-up depends on continued debt capacity and FCF conversion (TTM FCF $509.9M). Margins are structurally thin — 7.03% net and 16.86% gross — with Medicare and Medicaid supplying the majority of revenue, meaning a reimbursement rate cut or wage inflation spike could compress earnings disproportionately; interest coverage is strong ($2.3M expense vs. $140.2M pre-tax income), but that protects solvency, not profitability.
Market and competitive risks are dominated by valuation compression. At 24.0x EV/EBITDA, 1.97x PS, and 4.47x book, ENSG trades at a clear premium to skilled nursing peers that typically command mid-to-high single-digit EV/EBITDA multiples, and its 29.0x trailing PE sits near the top of its own 20–30x historical band. The stock's beta-like sensitivity is visible in its -31.83% max drawdown and its -6.00pp one-year relative strength versus SPY, showing it is not a defensive hedge despite its healthcare classification. Regulatory exposure to Medicare/Medicaid reimbursement and labor cost inflation are persistent sector headwinds, and thin analyst coverage (4 analysts, one Hold) means negative news can move the stock more than for large-cap peers.
The worst-case scenario is a reimbursement tightening or integration stumble that stalls margin expansion while the multiple compresses. In that chain — Q4 gross margin slipping back toward the 16.4% Q1 level, acquisition cadence slowing, and the forward EPS estimate drifting toward the $8.71 low — the stock could retrace to its June 11 low of $147.13, roughly -22% from the current $188.41, and a broader de-rating toward the low end of its historical PE band could push it further toward the $140s, a decline of roughly -25% to -30%. That is consistent with the -31.83% max drawdown already observed in the period, so investors should treat a 25–30% drawdown as a realistic adverse outcome rather than a tail event.
FAQ
The most severe risk is reimbursement and margin compression: with Medicare and Medicaid supplying the majority of revenue and net margin at only 7.03% (gross margin 16.86%), a single rate adjustment or wage-inflation spike hits earnings disproportionately given how little buffer exists. Second is valuation compression — at 24.0x EV/EBITDA, 1.97x PS, and 4.47x book, ENSG trades at a clear premium to peers at mid-to-high single-digit EV/EBITDA, and its 29.0x trailing PE sits near the top of its historical band, so a de-rating alone could erase a large share of returns. Third is the acquisition-dependent growth model: Q3 required $164.0M of acquisition outlays against $240.2M of operating cash flow, and debt-to-equity is 1.86x, meaning the growth rate is partly a financing decision that depends on continued debt capacity and FCF conversion. Fourth is company-specific volatility and thin coverage — only 4 analysts follow the stock with an 18% EPS spread, and the -31.83% max drawdown within the observed period shows the shares can swing 30%+ peak-to-trough despite the healthcare label, so position sizing should reflect that.
The 12-month forecast splits into three scenarios. The base case carries 50% probability with a $185-$205 target range, assuming EPS lands near the $9.57 consensus, gross margin holds at or above 16.86%, and the multiple stays near ~20x forward — a grind higher in line with earnings growth. The bull case carries 25% probability with a $210-$230 range, driven by EPS reaching the $10.27 high end of the analyst range, continued accretive deal flow, and a decisive breakout above $190 on volume that invites momentum buyers. The bear case carries 25% probability with a $147-$165 range, in which integration slows, gross margin retraces toward the 16.4% Q1 level, EPS drifts toward the $8.71 low, and the stock retraces to the June 11 low of $147.13 — roughly -22% from $188.41. The base case is most likely, and its key assumption is that the acquisition cadence continues at a pace fundable from the $509.9M TTM free cash flow and existing debt capacity without a reimbursement shock.
ENSG screens as fairly valued to modestly full rather than cheap. On trailing earnings the PE is 29.0x, near the top of its own 20-30x historical band (it was 23.9x at Q3 2026, 29.1x in Q1 2026, and 26.2x at year-end 2025), while the forward multiple of roughly 19.7x on the $9.57 consensus EPS is far more reasonable and implies the market expects about 47% earnings growth. The premium is clearest on non-earnings metrics: 1.97x price-to-sales, 4.47x price-to-book, and 24.0x EV/EBITDA are rich for a skilled nursing operator, where peers typically trade at mid-to-high single-digit EV/EBITDA multiples. That premium is partly earned — 14.47% revenue growth versus low-single-digit sector norms and a 15.41% ROE justify paying up for quality — but it means the market is already pricing in continued double-digit growth and margin expansion. The practical read is that further upside likely has to come from earnings beats rather than multiple expansion, and any execution miss would leave the 24.0x EV/EBITDA multiple exposed to compression.
From a risk/reward standpoint ENSG is a reasonable but not compelling entry at $188.41, because the stock sits at 100% of its 180-day range and just above the November 4 high of $188.31, leaving essentially no valuation cushion. The reward case is real: revenue is growing 14.47% YoY, gross margin has expanded for three straight quarters (16.40% → 16.65% → 16.86%), and the ~19.7x forward multiple on the $9.57 consensus EPS is well below the 29.0x trailing PE, implying roughly 47% expected earnings growth. The downside case is equally concrete: at 24.0x EV/EBITDA and 1.97x PS the stock trades at a premium to skilled nursing peers, and it has already demonstrated a -31.83% max drawdown, with the June 11 low of $147.13 sitting about -22% below the current price. Analyst sentiment is constructive but thin — 3 Buy/Outperform versus 1 Hold across only 4 analysts, with an 18% EPS dispersion ($8.71-$10.27) that signals genuine uncertainty. It is a good buy for growth-oriented investors with a multi-year horizon who accumulate on pullbacks toward the $169-$172 support shelf, and a poor entry for anyone seeking a defensive healthcare name or a quick trade at the highs.
ENSG is better suited to a long-term holding period of at least 3-5 years than to short-term trading. The business is a compounding roll-up whose value comes from repeatedly acquiring underperforming facilities and improving their operations — a process that plays out over quarters, not weeks — and the earnings visibility is reasonable given 14.47% revenue growth and three consecutive quarters of margin expansion. However, the volatility profile argues against a short leash: the -31.83% max drawdown within the observed period and the stock's non-defensive behavior (one-year relative strength of -6.00pp versus SPY despite the healthcare label) mean a short-term trader could be stopped out by a 25-30% swing even in an intact uptrend. The dividend is negligible at a 0.14% yield and 4.19% payout ratio, so there is no income component to support a hold through drawdowns. A practical approach is a core position built over time with accumulation on pullbacks toward the $169-$172 support shelf, reviewed quarterly against the gross-margin and acquisition-cadence tests rather than against daily price action.

